Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9748
Full metadata record
DC FieldValueLanguage
dc.contributor.authorNorman, Trevor Ren
dc.contributor.authorOlver, James Sen
dc.date.accessioned2015-05-15T22:57:17Z
dc.date.available2015-05-15T22:57:17Z
dc.date.issued2004en
dc.identifier.citationCns Drugs; 18(8): 505-20en
dc.identifier.govdoc15182220en
dc.identifier.otherPUBMEDen
dc.identifier.urihttp://ahro.austin.org.au/austinjspui/handle/1/9748en
dc.description.abstractFor nearly 50 years, antidepressant drugs have been the first-line treatment for various forms of depression. Despite their widespread use, these medications have significant shortcomings, in particular problems of patient compliance due to adverse effects. The introduction of new formulations of existing antidepressant medications may provide patients with benefits in terms of convenience of use. As a consequence, improvements in compliance may lead to better antidepressant efficiency.An orally disintegrating formulation of mirtazapine (mirtazapine SolTab), a once-weekly formulation of fluoxetine, an enantiomer-specific formulation of citalopram (escitalopram), an extended-release formulation of venlafaxine (venlafaxine XR), a controlled-release formulation of paroxetine (paroxetine CR) and intravenous formulations of some of the newer antidepressants have all been evaluated in limited clinical trials. In this article, a review of the pharmacokinetics and clinical evaluations of these formulations is presented. While there do not appear to be major clinical advantages for the new formulations in terms of antidepressant efficacy, none of them is less efficacious than their older counterpart. Indeed, some of the new formulations are more acceptable to patients (fluoxetine once-weekly, paroxetine CR), others have pharmacokinetic advantages (venlafaxine XR, paroxetine CR), while others may have a faster onset of effect (mirtazapine SolTab, intravenous formulations). Further evaluation of some formulations is still required (mirtazapine SolTab, fluoxetine once-weekly), while others (venlafaxine XR, escitalopram) are finding widespread acceptance in clinical practice.en
dc.language.isoenen
dc.subject.otherAnimalsen
dc.subject.otherAntidepressive Agents.chemistry.therapeutic useen
dc.subject.otherAntidepressive Agents, Second-Generation.chemistry.pharmacology.therapeutic useen
dc.subject.otherAntidepressive Agents, Tricyclic.pharmacology.therapeutic useen
dc.subject.otherChemistry, Pharmaceuticalen
dc.subject.otherCyclohexanols.chemistry.pharmacology.therapeutic useen
dc.subject.otherDelayed-Action Preparationsen
dc.subject.otherDepression.drug therapyen
dc.subject.otherDrug Evaluationen
dc.subject.otherFluoxetine.chemistry.pharmacology.therapeutic useen
dc.subject.otherHumansen
dc.subject.otherMianserin.analogs & derivatives.chemistry.pharmacology.therapeutic useen
dc.subject.otherMolecular Conformationen
dc.titleNew formulations of existing antidepressants: advantages in the management of depression.en
dc.typeJournal Articleen
dc.identifier.journaltitleCNS drugsen
dc.identifier.affiliationDepartment of Psychiatry, University of Melbourne, Austin & Repatriation Medical Centre, Heidelberg, Victoria, Australiaen
dc.description.pages505-20en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/15182220en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.fulltextNo Fulltext-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.cerifentitytypePublications-
crisitem.author.deptPsychiatry (University of Melbourne)-
crisitem.author.deptPsychiatry (University of Melbourne)-
Appears in Collections:Journal articles
Show simple item record

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.